eMedicals Healthtech GmbH

eMedicals Healthtech GmbH website preview
medtech Frankfurt am Main 1 source
Own this company? Claim the page to unlock editing and verified-owner badge.

Founded in 2020, eMedicals Healthtech develops a plant biochemical platform for novel therapeutics and pioneers AI analytics and biomarkers for Chronic Kidney Disease and Cardiometabolic Diseases.

Classification

Frankfurt am Main DE medtech other b2b aibioinformatics HealthAI

Profile

Founded
2020
Tech stack
AI analytics, plant biochemical platform

Funding

Funding details not yet available.

Signals

Business model
💡 Value Proposition

Delivering innovative food-based drug delivery systems that use everyday foods to improve medication efficacy and patient adherence for nutrition-sensitive diseases.

👥 Customer Segments

Patients with chronic kidney disease, type 2 diabetes, and cardiovascular disease, alongside healthcare providers and industry partners in life sciences.

💰 Revenue Model

SaaS subscription fees - tiered per-user pricing for clinicians, per-patient pricing for insurers · Data-licensing fees - anonymised RWD sold to pharma/biotech for research & post-marketing surveillance · Implementation & integration services - one-off fees for EHR integration, training, and customization

📡 Channels

Direct B2B sales force - targeting hospital networks, dialysis centres, and insurer procurement teams · Strategic partnerships - with electronic health record (EHR) vendors and laboratory services for data integration · Clinical conferences & webinars - thought-leadership to reach clinicians and payers (e.g., guest lecture at University of Marburg

🤝 Key Partnerships

EHR & health-IT vendors - for seamless data exchange (e.g., SAP Health, Cerner) · Laboratories & genomics providers - to supply nutrigenomic data · Academic hospitals & research institutes - for clinical validation (e.g., University Hospital Frankfurt)

⚖️ Cost Structure

R&D for biochemical platforms and next-generation AI solutions, plus operational costs for company management in Frankfurt.

🏗️ Key Resources

Proprietary biochemical platform for drug delivery, AI technologies for nutrition-sensitive diseases, and specialized team expertise in life sciences and healthtech.

⚙️ Key Activities

Developing novel therapeutics using nutrigenomics and AI, and advancing food-based active pharmaceutical ingredient delivery systems.

💬 Customer Relationships

High-touch onboarding - dedicated implementation specialists for hospitals/insurers · Subscription-based support - 24/7 technical help desk and periodic clinical training webinars · Data-sharing agreements - transparent consent management to build trust with patients and pharma partners

Strategic analysis
🏁 Competitive landscape

Competes at the intersection of life sciences and healthtech by combining food-based delivery with AI for chronic disease management.

🎯 Market pains

Poor medication adherence and ineffective progression control for chronic nutrition-sensitive diseases like CKD, T2D, and CVD.

💎 Improvement suggestions
  • Validate the outcome claim - Run a controlled pilot with at least one insurer to quantify reductions in dialysis initiation; use results
♟️ Strategic implications
  • Regulatory status: Has the kidi platform obtained any medical-device certification (CE-Mark, FDA 510(k))?
Investors

No investors recorded yet.

Sources & references

Web verified · 1 source
Enriched 18 Jun 2026